A Radium-223 microgenerator from cyclotron-produced trace Actinium-227.

The alpha particle emitter Radium-223 dichloride (RaCl) has recently been approved for treatment of late-stage bone metastatic prostate cancer. There is considerable interest in studying this new agent outside of the clinical setting, however the supply of Ra is limited and expensive. We have engineered a Ra microgenerator using traces of Ac previously generated from cyclotron-produced Ac.